Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Account Payables: 2013-2024

Historic Change in Account Payables for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$2.9 million.

  • Seres Therapeutics' Change in Account Payables fell 1455.26% to -$515,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year decrease of 71.97%. This contributed to the annual value of -$2.9 million for FY2024, which is 74.61% up from last year.
  • Latest data reveals that Seres Therapeutics reported Change in Account Payables of -$2.9 million as of FY2024, which was up 74.61% from -$11.6 million recorded in FY2023.
  • Seres Therapeutics' 5-year Change in Account Payables high stood at $9.4 million for FY2021, and its period low was -$11.6 million during FY2023.
  • Its 3-year average for Change in Account Payables is -$4.1 million, with a median of -$2.9 million in 2024.
  • Its Change in Account Payables has fluctuated over the past 5 years, first spiked by 907.77% in 2021, then plummeted by 625.56% in 2023.
  • Seres Therapeutics' Change in Account Payables (Yearly) stood at -$1.2 million in 2020, then spiked by 907.77% to $9.4 million in 2021, then tumbled by 76.47% to $2.2 million in 2022, then tumbled by 625.56% to -$11.6 million in 2023, then spiked by 74.61% to -$2.9 million in 2024.